124I-Evuzamitide Positron Emission Tomography/Computed Tomography for Diagnosing Cardiac Amyloidosis: The…

StudyJAMA· Aug 2026

124I-Evuzamitide Positron Emission Tomography/Computed Tomography for Diagnosing Cardiac Amyloidosis: The REVEAL Nonrandomized Clinical Trial.

Sharmila Dorbala, Mathew S Maurer, Sarah A M Cuddy … REVEAL Study Investigators

Cardiovascular ImagingStudyDiagnosis

124I-evuzamitide positron emission tomography/computed tomography shows high sensitivity for diagnosing cardiac amyloidosis.

124I-Evuzamitide Positron Emission Tomography/Computed Tomography for Diagnosing Cardiac Amyloidosis: The REVEAL Nonrandomized Clinical Trial.

Sharmila Dorbala … REVEAL Study Investigators

JAMA · Aug 2026

Background

IMPORTANCE: Diagnosing cardiac amyloidosis remains challenging because current imaging approaches are limited to transthyretin amyloidosis.

Purpose

To evaluate the sensitivity and specificity of 124I-evuzamitide positron emission tomography (positron emission tomography)/computed tomography (computed tomography) for diagnosing cardiac amyloidosis.

Methods

DESIGN, SETTING, AND PARTICIPANTS: Prospective, multicenter (18 US centers), single-group study evaluating the efficacy of 124I-evuzamitide to diagnose cardiac amyloidosis.

n = 195 adults

Results

The positron emission tomography/computed tomography accurately detects nearly all patients with cardiac amyloidosis

94%

Sensitivity

86%

Specificity

More results

Median N-terminal pro-brain natriuretic peptide was 471 pg/mL and 61.7% had New York Heart Association class II or III heart failure symptoms.

“

Conclusion · 1 of 2

124I-evuzamitide positron emission tomography/computed tomography is highly sensitive and specific for diagnosing cardiac amyloidosis with an acceptable safety profile.

Conclusion · 2 of 2

These results support 124I-evuzamitide positron emission tomography/computed tomography as a diagnostic test to evaluate patients with suspected cardiac amyloidosis.

124I-Evuzamitide Positron Emission Tomography/Computed Tomography for Diagnosing Cardiac Amyloidosis: The REVEAL Nonrandomized Clinical Trial.

124I-Evuzamitide Positron Emission Tomography/Computed Tomography for Diagnosing Cardiac Amyloidosis: The REVEAL Nonrandomized Clinical Trial.

Related papers